WeWork Announces Date of Second Quarter 2022 Results Conference Call
Get Alerts WE Hot Sheet
Join SI Premium – FREE
NEW YORK--(BUSINESS WIRE)-- WeWork Inc. (NYSE: WE) (“WeWork”), one of the leading global flexible space providers, today announced that on Thursday, August 4, 2022, it will issue financial results for the second quarter ending June 30, 2022. The company will conduct a conference call at 8:00 (ET), following the release of its earnings materials.
Earnings call details, the company’s earnings release, and related materials will be available on WeWork’s Investor Relations website at investors.wework.com. A replay of the conference call will be available at the same website after the call.
WeWork announces material information to the public through a variety of means, including filings with the Securities and Exchange Commission, press releases, public conference calls, webcasts and the investor relations section of its website (investors.wework.com) in order to achieve broad, non-exclusionary distribution of information to the public and for complying with its disclosure obligations under Regulation FD.
About WeWork:
WeWork (NYSE: WE) was founded in 2010 with the vision to create environments where people and companies come together and do their best work. Since then, we’ve become one of the leading global flexible space providers committed to delivering technology-driven turnkey solutions, flexible spaces, and community experiences. For more information about WeWork, please visit us at wework.com.
Category: Investor Relations
View source version on businesswire.com: https://www.businesswire.com/news/home/20220715005237/en/
Investor Relations:
Kevin Berry
[email protected]
Press:
Nicole Sizemore
[email protected]
Source: We Work
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- BioNTech and Bristol Myers Squibb report Phase 2 data for pumitamig in NSCLC
- Positive Overall Survival Results from the Phase III HARMONi-GI1 Trial of Ivonescimab Plus Chemotherapy Versus Durvalumab Plus Chemotherapy in First-Line Biliary Tract Cancer Presented at the ESMO 202
- Sonesitatug vedotin reduced the risk of death by 42% in 2nd and later-line CLDN18.2-positive advanced gastric/GEJ cancers in CLARITY-Gastric01
Create E-mail Alert Related Categories
Business Wire, Press ReleasesRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!





Tweet
Share